The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11150 malaria professionals are enjoying the free benefits of MalariaWorld today

artemisinin

Adverse drug events resulting from use of drugs with sulphonamide-containing anti-malarials and artemisinin-based ingredients: findings on incidence and household costs from three districts with routine demographic surveillance systems in rural Tanzania

July 16, 2013 - 15:51 -- Open Access
Author(s): 
Njau JD, Kabanywanyi AM, Goodman CA, MacArthur JR, Kapella BK, Gimnig JE, Kahigwa E, Bloland PB, Abdulla SM, Kachur SP
Reference: 
Malaria Journal 2013, 12:236 (11 July 2013)
MalariaWorld

This study aimed to document ADR incidence and associated household costs in three high malaria transmission districts in rural Tanzania covered by demographic surveillance systems.

Country: 

Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy

June 28, 2013 - 18:21 -- Open Access
Author(s): 
Sanjeev Krishna, Peter Gottfried Kremsner
Reference: 
Trends in Parasitology, Volume 29, Issue 7, July 2013, Pages 313-317
MalariaWorld

This opinion article reviews the mechanisms underlying parasite clearance after artemisinin treatment and how these might relate to in vitro methods to assay for resistance.

Artemisinin resistance in Plasmodium falciparum: what is it really?

June 28, 2013 - 18:18 -- Open Access
Author(s): 
Pedro Eduardo Ferreira, Richard Culleton, Jose Pedro Gil, Steven Richard Meshnick
Reference: 
Trends in Parasitology, Volume 29, Issue 7, July 2013, Pages 318-320
MalariaWorld

To properly assess the danger posed by artemisinin resistance, and therefore enable appropriate and proportionate responses, definitions of ‘artemisinin resistance’ and ‘ACT resistance’, at both the clinical and parasitological levels, are needed.

MMV in partnership: the Eurartesim(R) experience

June 24, 2013 - 15:30 -- Open Access
Author(s): 
Ubben D, Poll EM
Reference: 
Malaria Journal 2013, 12:211 (19 June 2013)
MalariaWorld

This case study describes how a public-private partnership between Medicines for Malaria Venture (MMV) and Sigma-Tau Industrie Farmaceutiche Riunite SpA achieved international regulatory approval for use of the fixed-dose artemisinin-based combination therapy dihydroartemisinin-piperaquine (Eurartesim(R)) for the treatment of malaria, enabling more widespread access to the medicine in malaria-endemic countries.

Designing the next generation of medicines for malaria control and eradication

June 14, 2013 - 13:27 -- Open Access
Author(s): 
Burrows JN, Hooft van Huijsduijnen R, Möhrle JJ, Oeuvray C, Wells TN
Reference: 
Malaria Journal 2013, 12:187 (6 June 2013)
MalariaWorld

In this paper, an outline definition of the ideal and minimally acceptable characteristics of the types of clinical candidate molecule which are needed (target candidate profiles) is suggested. In addition, the optimal and minimally acceptable characteristics of combination medicines are outlined (target product profiles). 

Artemisinin based combination therapy in travel medicine

April 15, 2013 - 18:11 -- Open Access
Author(s): 
Tomas Jelinek
Reference: 
Travel Medicine and Infectious Disease, Volume 11, Issue 1, January–February 2013, Pages 23-28
MalariaWorld

 In this setting, artemisinin combinations should be available for treatment of uncomplicated malaria as they are clearly superior to any other oral antimalarial in their fast reduction of parasite biomass and in decreasing clinical symptoms. 

Rational engineering plasticity residues of sesquiterpene synthases from Artemisia annua: product specificity and catalytic efficiency

February 28, 2013 - 15:30 -- Open Access
Author(s): 
Jian-Xu Li, Xin Fang, Qin Zhao, Ju-Xin Ruan, Chang-Qing Yang, Ling-Jian Wang, David J Miller, Juan A Faraldos, Rudolf K Allemann, Xiao-Ya Chen and Peng Zhang
Reference: 
Biochem. J. (2013)
MalariaWorld

Here, we report a new sesquiterpene synthase from A. annua, α-bisabolol synthase (AaBOS), which has high sequence identity to amorpha-4,11-diene synthase (AaADS), a key enzyme in artemisinin biosynthesis.

Not Open Access | Mutation analysis in pfmdr1 and pfmrp1 as potential candidate genes for artemisinin resistance in Plasmodium falciparum clinical isolates 4 years after implementation of artemisinin combination therapy in Iran

February 12, 2013 - 17:41 -- NOT Open Access
Author(s): 
Sakineh Pirahmadi, Sedigheh Zakeri, Mandana Afsharpad, Navid Dinparast Djadid
Reference: 
Infection, Genetics and Evolution, Volume 14, March 2013, Pages 327-334
MalariaWorld

The present study provides information on genetic analysis in multidrug resistance 1 (pfmdr1) (N86Y/Y184F/S1034C/N1042D/F1226Y/D1246Y) and multidrug resistance protein 1 (pfmrp1) (H191Y/S437A/I876V/F1390I/K1466R) genes that are probably associated with artemisinin as well as chloroquine resistance transporter (pfcrt) 76T in P. falciparum clinical isolates (N = 200) exposed to artemisinin-based combination therapy (ACT) 4 years after its adoption in Iran.

Not Open Access | Transitioning from malaria control to elimination: the vital role of ACTs

February 5, 2013 - 16:14 -- NOT Open Access
Author(s): 
Heiner Grueninger, Kamal Hamed
Reference: 
Trends in Parasitology, Volume 29, Issue 2, February 2013, Pages 60-64
MalariaWorld

In this opinion paper, the requirements for the continued success of ACTs, their role in this transition, and possible new ways of using these drugs in an elimination setting are discussed. ACTs have an important role to play in maintaining the current success of control programs, and may also drive these successes forward into the widespread elimination of malaria.

Increasing incidence of malaria in children despite insecticide-treated bed nets and prompt anti-malarial therapy in Tororo, Uganda

December 31, 2012 - 10:55 -- Open Access
Author(s): 
Jagannathan P, Muhindo MK, Kakuru A, Arinaitwe E, Greenhouse B, Tappero J, Rosenthal PJ, Kaharuza F, Kamya MR, Dorsey G
Reference: 
Malaria Journal 2012, 11:435 (28 December 2012)
MalariaWorld

Reported compliance with LLINs was 98% based on monthly routine evaluations. A total of 1,633 episodes of malaria were observed, with a median incidence of 5.3 per person-year (PPY).

Pages

Subscribe to RSS - artemisinin